Collegium Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Collegium Pharma (COLL) Posts Q1 Loss of $0.29/Sh
May 8, 2019 4:51 PM EDTCollegium Pharma (NASDAQ: COLL) reported Q1 EPS of ($0.29), which may not compare to the analyst estimate of ($0.24). Revenue for the quarter came in at $74.5 million versus the consensus estimate of $70.82 million.
For earnings history and earnings-related data on Collegium Pharma (COLL) click here.
... More